Press Releases
To the Nasdaq Copenhagen
Prepayments (CK93)
Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 3 May 2024 in the attached file.
Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For further... (continue reading...)
To the Nasdaq Copenhagen
Prepayments (CK93)
Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 3 May 2024 in the attached file.
Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For further... (continue reading...)
In todays fast-paced world, where leisure time is a cherished treasure, finding engaging and meaningful activities for relaxation is crucial. JILIBET Games emerges as a beacon of entertainment, offering a diverse portfolio that caters to a wide range of interests and hobbies outside the realm of casino and gambling. This exploration unveils the multifaceted world of JILIBET Games in the Philippines, emphasizing the boundless opportunities for fun, skill development,... (continue reading...)
STOCKHOLM, May 6, 2024 /PRNewswire/ -- Stockholm Exergi today announced that it has signed a contract with Microsoft covering 3.33 million tonnes of permanent carbon removals from bio-energy with carbon capture and storage (BECCS) at Värtan, Stockholm. The agreement represents the world's largest permanent removals deal to date. The deliveries of the carbon removal certificates to Microsoft are planned to start in 2028 and continue for a period of ten years.
"The... (continue reading...)
6 May 2024
Notification no. 48/2024
Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.
In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.
For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons... (continue reading...)
More Press Releases
View Older Stories-
ZTE's science-based targets approved by SBTi
-
First Hydrogen's Vehicle Trials with Multinational Company
-
IberAmerican Engages Senior Commodities Strategist
-
Successful Conclusion of SOUEAST Motor Global Investment Promotion Conference: Launching a New Chapter in Globalization Strategy
-
Reporting of transactions made by members of the Board of Directors or Executive Management or their Closely Associated Persons
-
Restructuring of ownership in BW Energy Limited and exemption from the mandatory offer obligation
-
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
-
OKX Ventures Announces Strategic Investment in EVG's Consumer-oriented Projects, Paving the Way for Novel Applications in SocialFi and GameFi
-
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
-
SINOX Group to Showcase the Latest Synlox e-Security System at Eurobike
-
Rimsys Launches Community-Driven Regulatory Intelligence
-
SINOX Group to Showcase Universal Laptop Locks Aligning with the AI Era at Computex Taipei 2024
-
Oma Savings Bank Plc: Manager´s Transactions – Closely associated person Tanja Mäkynen
-
Oma Savings Bank Plc: Manager´s Transactions – Jyrki Mäkynen
-
Share buy-back programme - week 18
-
Elbit Systems Schedules First Quarter 2024 Results Release For May 28, 2024
-
INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas
-
LHV Pank to contest the fine decision by Estonian Financial Intelligence Unit
-
Renault Group: Communication related to the availability of the EMTN base prospectus 2024
-
Transactions in connection with share buyback programme
-
Preliminary data on early redemptions (prepayments)
-
Pierre Anjolras appointed Chief Operating Officer of VINCI
-
Marimekko celebrates the 60th anniversary of the Unikko print in Helsinki and Tokyo with public open-air fashion shows
-
QUADIENT: 2024 Financial calendar - Update
-
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
-
Exor Press Release - Periodic Report on the Buyback Program
-
Graphano Expands Zone 3 at LAB Graphite Project - Reports Remaining Program Results including 15.65 Metres Grading 7.91% Cg
-
KKR to Acquire Healthium from Apax Funds
-
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
-
BrainChip and Frontgrade Gaisler to Augment Space-Grade Microprocessors with AI Capabilities
-
Xylem Unveils 'Reuse Brew'
-
SES to acquire Intelsat: Investor Relations Frequently Asked Questions
-
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
-
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
-
Aktsiaselts Infortar interim report for Q1 2024
-
Fingerprints and Infrafon collaborating on new smart badges for the European Medical and IoT market
-
Subsea7 share repurchases
-
M&P Receives a Specific License From the OFAC in Relation to Its Operations in Venezuela
-
Statement Concerning Eutelsat Group’s Ground Network
-
Ambri Agrees to Terms of Proposed Sale with Lender Consortium
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Transaction in Own Shares
-
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757